IBIO — iBio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1420720 ·
Last close
$1.19
Market Cap
$76.53M
52W High
$3.82
52W Low
$0.78
ADV30
739,163
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -6,377,000 | -10,601,000 | 99,110,000 | 56,395,000 | 13,397,000 |
| Mar 2026 | 0 | — | -8,365,000 | -7,730,000 | 85,834,000 | 47,631,000 | 8,297,000 |
| Dec 2025 | 0 | — | -9,445,000 | -8,993,000 | 64,393,000 | 28,672,000 | 7,833,000 |
| Sep 2025 | 100,000 | — | -5,951,000 | -5,720,000 | 64,155,000 | 28,111,000 | 8,116,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,605,000
Investing CF
$-27,542,000
Financing CF
$91,824,000
CapEx
$-560,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.75
As of
2026-08-30
Balance + Analyst (yfinance extras)
Retained Earnings
$-354,667,000
Inventory
—
Receivables
$0
ST Investments
$27,166,000
EBIT TTM
$-27,463,000
Pretax Income TTM
$-27,606,000
Interest Exp TTM
$143,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$100,000
EBITDA
$-29,492,000
Free Cash Flow
$-13,621,375
Enterprise Value
$-8,350,756
Total Cash
$88,039,000
Total Debt
$2,198,000
Shares Out
64,307,256
Trailing EPS
$-0.32
Book Value
$1.54
ROE
-65.7%
ROA
-30.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 100,000 | -30,138,000 | -33,044,000 | 99,110,000 | 13,397,000 | 85,713,000 | -23,218,000 |
| Jun 2025 | 400,000 | -18,602,000 | -18,377,000 | 23,185,000 | 8,305,000 | 14,880,000 | -15,304,000 |
| Jun 2024 | 225,000 | -16,634,000 | -24,907,000 | 28,734,000 | 7,410,000 | 21,324,000 | -18,554,000 |
| Jun 2023 | 0 | -29,343,000 | -65,010,000 | 41,207,000 | 25,826,000 | 15,381,000 | -30,436,000 |
| Jun 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$223,000
NetIncome TTM
$-26,750,000
OpCashFlow TTM
$0
Assets (Latest)
$23,185,000
Forward EPS
$-0.61
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FBIO | Fortress Biotech, Inc. | $76.04M | $2.28 | — |
| GANX | Gain Therapeutics, Inc. | $77.69M | $1.78 | — |
| OSTX | OS Therapies Inc | $77.70M | $1.66 | — |
| VRCA | Verrica Pharmaceuticals Inc. | $75.07M | $4.37 | — |
| INCR | Intercure Ltd. | $78.17M | $5.21 | — |
News headlines (Yahoo Finance, 1h cache)
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
2026-09-01 20:30 · Yahoo
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-08-28 11:00 · Yahoo
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
2026-07-01 11:00 · Yahoo
Could iBio (IBIO) Be an Underrated Obesity Stock?
2026-06-12 00:37 · Yahoo
iBio to Participate in Upcoming Healthcare Investor Conferences
2026-06-02 20:01 · Yahoo
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-05-12 20:05 · Yahoo
iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
2026-05-08 11:15 · Yahoo
iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”
2026-04-08 22:13 · Yahoo
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
2026-08-04 11:00 · Yahoo
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
2026-06-02 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.